Investigating new treatments for liver damage caused by alcohol and obesity
Development and Preclinical Evaluation of Nanoformulations in Liver Fibrotic Mice
This study is looking at new treatments for liver damage caused by alcohol and obesity, using mice to test a special drug that could help prevent inflammation and scarring in the liver, with the hope of finding better options for people with liver problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11054647 on NIH RePORTER |
What this research studies
This research focuses on developing and testing new nanoformulations aimed at treating liver damage resulting from alcohol abuse and obesity. It explores how liver cell damage leads to inflammation and fibrosis, and how specific signaling pathways can be targeted to prevent these conditions. The study utilizes preclinical models, specifically mice, to evaluate the effectiveness of a novel inhibitor that targets the Hedgehog signaling pathway, which is implicated in liver fibrosis. By understanding these mechanisms, the research aims to identify potential therapeutic strategies for patients suffering from liver-related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from liver damage due to alcohol abuse or obesity-related conditions.
Not a fit: Patients with liver damage from causes other than alcohol abuse or obesity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve liver health and reduce the risk of cirrhosis in patients with alcohol-related liver disease and obesity.
How similar studies have performed: Previous research has shown promise in targeting similar pathways for liver disease treatment, indicating potential for success in this approach.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Mahato, Ram I. — University of Nebraska Medical Center
- Study coordinator: Mahato, Ram I.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.